Elizabeth Christine Radigan
CIK 1967040 · View on SEC EDGAR ↗
First SEC filing: Feb. 24, 2023 · Latest: March 3, 2025
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 1, 2025 | DBD | F | 1,043 | $44.23 | $46,132 | 24,647 Direct | -4.06% | Disposed | 53.9% (price as of 2026-08-21) |
| March 1, 2025 | DBD | A | 8,292 | — | — | 25,690 Direct | +47.66% | Acquired | (price as of 2026-08-21) |
| Jan. 19, 2025 | DBD | F | 746 | $44.49 | $33,190 | 17,398 Direct | -4.11% | Disposed | 53.0% (price as of 2026-08-21) |
| March 1, 2024 | DBD | A | 10,005 | — | — | 18,144 Direct | +122.93% | Acquired | (price as of 2026-08-21) |
| Jan. 19, 2024 | DBD | A | 40,696 | — | — | 40,696 Direct | — | Acquired | (price as of 2026-08-21) |
| Jan. 19, 2024 | DBD | A | 8,139 | — | — | 8,139 Direct | — | Acquired | (price as of 2026-08-21) |
| Aug. 11, 2023 | DBD | J | 29,562 | — | — | 0 Direct | -100.00% | Disposed | (price as of 2026-08-21) |
| March 8, 2023 | DBD | F | 1,073 | $3.21 | $3,444 | 29,562 Direct | -3.50% | Disposed | 2020.9% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 19, 2024 | DBD | Employee Stock Option (right to buy) | Common Stock (40,696) | $30.90 | Jan. 19, 2034 | 40,696 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Feb. 24, 2023 | DBD | Common Shares | 30,635 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
DBD
Chief Legal Officer and Corporate Secretary| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | — | — | — | — | $393,077 | — | — | $1,299,346 |
| 2022 | — | — | — | — | — | — | — | — |
| 2021 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.